PSNL vs. XGN, DMTK, BDSX, PTWO, GNTA, ALGS, NVNO, IKNA, EGRX, and LTRN
Should you be buying Personalis stock or one of its competitors? The main competitors of Personalis include Exagen (XGN), DermTech (DMTK), Biodesix (BDSX), Pono Capital Two (PTWO), Genenta Science (GNTA), Aligos Therapeutics (ALGS), enVVeno Medical (NVNO), Ikena Oncology (IKNA), Eagle Pharmaceuticals (EGRX), and Lantern Pharma (LTRN). These companies are all part of the "medical" sector.
Personalis (NASDAQ:PSNL) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment, analyst recommendations and community ranking.
Exagen has a net margin of -45.08% compared to Personalis' net margin of -147.38%. Personalis' return on equity of -61.42% beat Exagen's return on equity.
Personalis has a beta of 1.95, meaning that its share price is 95% more volatile than the S&P 500. Comparatively, Exagen has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500.
Exagen has lower revenue, but higher earnings than Personalis. Exagen is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.
Personalis received 89 more outperform votes than Exagen when rated by MarketBeat users. Likewise, 65.06% of users gave Personalis an outperform vote while only 52.78% of users gave Exagen an outperform vote.
Personalis currently has a consensus target price of $5.50, suggesting a potential upside of 340.00%. Exagen has a consensus target price of $6.00, suggesting a potential upside of 328.57%. Given Personalis' higher possible upside, research analysts plainly believe Personalis is more favorable than Exagen.
61.9% of Personalis shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 4.1% of Personalis shares are held by company insiders. Comparatively, 36.8% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Personalis and Personalis both had 1 articles in the media. Personalis' average media sentiment score of 0.00 equaled Exagen'saverage media sentiment score.
Summary
Personalis beats Exagen on 8 of the 14 factors compared between the two stocks.
Get Personalis News Delivered to You Automatically
Sign up to receive the latest news and ratings for PSNL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PSNL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Personalis Competitors List
Related Companies and Tools
